SynuSight Biotech has licensed 18 F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment . SHANGH ...
A novel PET imaging approach can effectively quantify a key enzyme associated with brain inflammation, according to research published in the March issue of The Journal of Nuclear Medicine. The ...
At the Yale Positron Emission Tomography (PET) Center, an ultra-high-performance brain-dedicated scanner called the NeuroEXPLORER (NX) is redefining what is possible in brain PET imaging. With a ...
10d
A brain-dedicated scanner is changing what doctors can see. CT researchers say that ‘opens the door’
The ability to follow patients with this high sensitivity allows us to make a more accurate and precise measurement, and we can see small changes or see them in a shorter period of time…,” ...
VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company ...
SynuSight Biotech ("SynuSight"), a biotechnology company dedicated to the development of diagnostic solutions for neurodegenerative diseases and ABLi Therapeutics ("ABLi"), a biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback